RANCHO CORDOVA, Calif.,
June 25, 2019 /PRNewswire/
-- ThermoGenesis Corp., a wholly owned subsidiary of Cesca
Therapeutics (Nasdaq: KOOL), and a market leader in automated
cellular processing, today announced that it has entered into
a strategic agreement with Cordlife Group Limited ("Cordlife
Group") to provide its proprietary, next-generation AXP®
II System, for the rapid processing of cord blood units, to
Cordlife's India processing
facility.
Cordlife Group, based in Singapore, is a leading provider of cord blood
banking services in Asia. The Group owns the largest network
of cord blood banks in Asia with
full stem cell processing and storage facilities in five key markets,
namely, Singapore,
Hong Kong, India, Indonesia and the
Philippines. Cordlife Sciences (India) Pvt. Ltd., operational since 2008 and
accredited by both AABB (the global gold standard in cord blood
banking) and the College of American Pathologists, is one of the
top three cord blood banks in India.
"Thermogenesis is rapidly building momentum for its proprietary
line of automated medical devices and technologies for cellular
processing, and this expanded relationship with Cordlife is a
testament to our ability to continuously innovate to provide better
technologies to our customers worldwide," said Haihong Zhu, ThermoGenesis' President. "Entry
into India, in addition to our
recently announced expansion into Thailand, will allow us to make a significant
impact in Asia, a large and very
important market for us."
AXP II provides automated, rapid and reliable harvesting of stem
and progenitor cells from collected units of umbilical cord blood
in a functionally closed sterile system and is currently used by
premier public and private cord blood banks, worldwide. The AXP II
System includes upgraded functionality, an enhanced user interface
and compatibility with newer operating systems and features an
improved docking station and XpressTRAK® software to
maintain compliance with Current Good Manufacturing Practice (cGMP)
and Current Good Tissue Practice (cGTP) regulations.
More About the AXP® II System
The
AXP® II System is a proprietary, automated system
for the isolation, collection and storage of hematopoietic stem
cell concentrates from cord blood. Its functionality:
- automates the volume reduction process,
- provides consistent buffy coat concentration volumes,
- ensures high recoveries of mononuclear cells in a targeted
final volume, and
- allows for simultaneous processing of multiple cord blood units
in one centrifuge.
Includes the AXP II Device, AXP II Docking Station, AXP
Processing Bag Set, XpressTRAK® software and
accessories.
About ThermoGenesis
ThermoGenesis develops,
commercializes and markets a full suite of solutions for automated
clinical biobanking, point-of-care applications, and automation for
immuno-oncology. The Company has developed an automated,
functionally-closed CAR-TXpress™ platform to streamline the
manufacturing process for the emerging CAR-T immunotherapy market.
For additional information, please visit:
www.thermogenesis.com.
About Cesca Therapeutics Inc.
Cesca Therapeutics
Inc. is a market leader in cell processing technologies and
autologous cell therapies for regenerative medicine. For more
information, visit: www.cescatherapeutics.com.
Company Contact:
Wendy
Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula
Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/cordlife-to-use-the-thermogenesis-axp-ii-system-for-rapid-processing-of-cord-blood-units-in-india-300874166.html
SOURCE Cesca Therapeutics